<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Health & Wellness Review — January 2026</title>
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Hanken+Grotesk:wght@400;500;600&display=swap" rel="stylesheet">
  <style>
    @font-face { font-family: 'Copernicus Trial'; src: url('fonts/CopernicusTrial-Book.ttf') format('truetype'); font-weight: 400; }
    @font-face { font-family: 'Copernicus Trial'; src: url('fonts/CopernicusTrial-Medium.ttf') format('truetype'); font-weight: 500; }
    *, *::before, *::after { margin: 0; padding: 0; box-sizing: border-box; }
    :root {
      --text-primary: #111111; --text-secondary: #44403C; --text-tertiary: #78716C;
      --bg-primary: #F9F9F9; --bg-secondary: #FDFDFD; --bg-tertiary: #F7F6F4; --bg-hover: #F5F4F3; --bg-white: #FFFFFF; --bg-accent: #2A8F87;
      --line-subtle: #E8E5E1; --line-default: #D5D2CD;
      --chart-primary: #2A8F87; --highlight-info: #E3EBF5;
      --serif: 'Copernicus Trial', Georgia, serif; --sans: 'Hanken Grotesk', -apple-system, sans-serif;
      --shadow-card: 0 4px 8px rgba(0,0,0,0.04), 0 2px 4px rgba(0,0,0,0.06);
      --shadow-card-hover: 0 8px 16px rgba(0,0,0,0.06), 0 4px 8px rgba(0,0,0,0.04);
      --radius: 24px;
    }
    html { font-size: 16px; } body { font-family: var(--sans); background: var(--bg-primary); color: var(--text-primary); line-height: 1.65; }
    .nav-bar { display: flex; justify-content: center; align-items: center; gap: 0; background: var(--bg-secondary); border-bottom: none; font-family: var(--sans); font-size: 0.8rem; font-weight: 500; letter-spacing: 0.04em; }
    .nav-bar a { text-decoration: none; color: var(--text-tertiary); padding: 0.7rem 1.5rem; margin: 4px 0; border-radius: 999px; transition: color 0.2s, background 0.2s; }
    .nav-bar a.active { color: var(--text-primary); background: #ECEAE7; }
    .sector-tabs { display: flex; justify-content: center; gap: 0.5rem; padding: 1rem 1.5rem; background: var(--bg-secondary); flex-wrap: wrap; }
    .sector-tab { font-family: var(--sans); font-size: 0.8rem; font-weight: 500; text-decoration: none; padding: 0.5em 1em; border-radius: 999px; border: none; color: var(--text-secondary); background: var(--bg-secondary); transition: all 0.2s; }
    .sector-tab:hover { background: var(--bg-hover); }
    .sector-tab.active { background: #ECEAE7; color: var(--text-primary); border: none; }
    .masthead { background: transparent; border-bottom: none; }
    .masthead-inner { max-width: 900px; margin: 0 auto; padding: 2.5rem 1.5rem 2rem; text-align: center; }
    .masthead .overline { font-size: 0.7rem; font-weight: 500; letter-spacing: 0.2em; text-transform: uppercase; color: var(--text-tertiary); margin-bottom: 0.75rem; }
    .masthead h1 { font-family: var(--serif); font-size: clamp(2rem, 5vw, 3rem); font-weight: 400; color: var(--text-primary); margin-bottom: 0.5rem; }
    .masthead .edition-date { font-size: 0.95rem; font-weight: 500; color: var(--text-secondary); }
    .masthead .edition-sub { font-size: 0.8rem; color: var(--text-tertiary); }
    .divider-bar { width: 60px; height: 3px; background: var(--text-primary); margin: 1rem auto 0; }
    .container { max-width: 900px; margin: 0 auto; padding: 2rem 1.5rem 4rem; }
    .section { margin-bottom: 3rem; }
    .section-header { display: flex; align-items: center; margin-bottom: 1.5rem; padding-bottom: 0.75rem; border-bottom: none; }
    .section-title { font-family: var(--serif); font-size: 1.35rem; font-weight: 500; color: var(--text-secondary); }
    .stat-grid { display: grid; grid-template-columns: repeat(4, 1fr); gap: 1rem; margin-bottom: 2rem; }
    @media (max-width: 640px) { .stat-grid { grid-template-columns: repeat(2, 1fr); } }
    .stat-card { background: var(--bg-secondary); border-radius: var(--radius); padding: 1.25rem; text-align: center; box-shadow: var(--shadow-card); }
    .stat-value { font-family: var(--serif); font-size: 1.75rem; font-weight: 500; color: var(--chart-primary); }
    .stat-label { font-size: 0.7rem; font-weight: 500; color: var(--text-tertiary); margin-top: 0.35rem; text-transform: uppercase; }
    .highlight-box { background: var(--highlight-info); border-radius: var(--radius); padding: 1.5rem; margin-bottom: 1.5rem; }
    .highlight-title { font-family: var(--serif); font-weight: 500; font-size: 1.1rem; margin-bottom: 0.75rem; color: var(--text-primary); }
    .highlight-box p { font-size: 1.125rem; color: var(--text-secondary); line-height: 1.6; }
    .highlight-box strong { color: var(--text-primary); }
    .cards { display: grid; gap: 1rem; }
    .card { background: var(--bg-secondary); border-radius: var(--radius); padding: 1.25rem 1.5rem; box-shadow: var(--shadow-card); transition: box-shadow 0.2s, transform 0.2s; }
    .card:hover { box-shadow: var(--shadow-card-hover); transform: translateY(-1px); }
    .card-headline { font-family: var(--serif); font-size: 1.25rem; font-weight: 500; margin-bottom: 0.4rem; color: var(--text-primary); }
    .card-body { font-size: 1.125rem; color: var(--text-secondary); line-height: 1.6; }
    .card-tag { display: inline-block; font-size: 0.65rem; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; padding: 0.2em 0.6em; border-radius: 999px; margin-bottom: 0.6rem; background: var(--bg-tertiary); color: var(--text-secondary); }
    .bottom-line { background: var(--bg-tertiary); border-radius: var(--radius); padding: 2rem; }
    .bottom-line .section-title { color: var(--text-secondary); }
    .bottom-line p { font-family: var(--sans); font-size: 1rem; line-height: 1.75; color: var(--text-secondary); }
    .footer { text-align: center; padding: 2rem 1.5rem 3rem; font-size: 0.75rem; color: var(--text-tertiary); border-top: 1px solid var(--line-subtle); max-width: 900px; margin: 0 auto; }
  </style>
</head>
<body>
  <nav class="nav-bar"><a href="live.html">Live</a><a href="index.html">Daily</a><a href="vc-review.html" class="active">Review</a><a href="archive.html">Archive</a></nav>
  <div class="sector-tabs">
    <a href="vc-review.html" class="sector-tab">VC</a><a href="ai-review.html" class="sector-tab">AI</a><a href="longevity-review.html" class="sector-tab">Longevity</a>
    <a href="health-wellness-review.html" class="sector-tab active">Health</a><a href="space-review.html" class="sector-tab">Space</a><a href="energy-review.html" class="sector-tab">Energy</a>
    <a href="sports-entertainment-review.html" class="sector-tab">Sports & Entertainment</a>
  </div>
  <header class="masthead"><div class="masthead-inner"><div class="overline">Daily Intelligence Brief</div><h1>Health & Wellness Review</h1><div class="edition-date">February 5, 2026</div><div class="edition-sub">GLP-1 Drugs · FDA Approvals · Clinical Breakthroughs · What to Watch</div><div class="divider-bar"></div></div></header>
  <main class="container">
    <section class="section"><div class="section-header"><h2 class="section-title">Market Overview</h2></div>
      <div class="stat-grid">
        <div class="stat-card"><div class="stat-value">24%</div><div class="stat-label">Retatrutide Weight Loss</div></div>
        <div class="stat-card"><div class="stat-value">180</div><div class="stat-label">Sepsis Trial Patients</div></div>
        <div class="stat-card"><div class="stat-value">98%</div><div class="stat-label">India CRISPR Cost Savings</div></div>
        <div class="stat-card"><div class="stat-value">$220M</div><div class="stat-label">Healthier Capital Fund I</div></div>
      </div>
      <div class="highlight-box"><div class="highlight-title">The Big Story</div><p>The GLP-1 drug revolution continues with <strong>Retatrutide showing up to 24% body weight loss</strong> — the most powerful weight loss drug ever in trials. Suzetrigine (Journavax) became the <strong>first opioid-free painkiller</strong> to receive FDA approval, while breakthrough sepsis and cancer vaccine trials showed promising results.</p></div>
    </section>
    <section class="section"><div class="section-header"><h2 class="section-title">GLP-1 Weight Loss Drugs</h2></div>
      <div class="cards">
        <article class="card"><span class="card-tag">Game Changer</span><h3 class="card-headline">Retatrutide: 24% Weight Loss — Most Powerful Ever</h3><p class="card-body">Triple agonist (GIP/GLP-1/Glucagon) showing up to <strong>24% body weight loss</strong> in Phase 3 trials — SUPERIOR to Ozempic/Wegovy.</p></article>
        <article class="card"><span class="card-tag">Market Leader</span><h3 class="card-headline">Mounjaro vs Ozempic: The Data</h3><p class="card-body">Mounjaro targets <strong>two hormones</strong> (GLP-1 + GIP) vs Ozempic's one. Real-world data suggests Mounjaro leads to greater weight loss.</p></article>
        <article class="card"><span class="card-tag">Orforglipron</span><h3 class="card-headline">Chugai: Oral GLP-1 FDA Approval Expected</h3><p class="card-body">FDA approval for obesity drug <strong>orforglipron</strong> expected — an oral alternative to injectable GLP-1s.</p></article>
      </div>
    </section>
    <section class="section"><div class="section-header"><h2 class="section-title">FDA Approvals & Breakthroughs</h2></div>
      <div class="cards">
        <article class="card"><span class="card-tag">Opioid-Free</span><h3 class="card-headline">Suzetrigine (Journavax): First Opioid-Free Painkiller</h3><p class="card-body">First NaV1.8 blocker to win FDA approval. <strong>Opioid-level pain relief without respiratory depression, sedation, or addiction risk</strong>.</p></article>
        <article class="card"><span class="card-tag">Fast Track</span><h3 class="card-headline">IHL-42X for Sleep Apnea Gets FDA Fast Track</h3><p class="card-body">IXHL's drug candidate IHL-42X received <strong>Fast Track designation</strong> for obstructive sleep apnea treatment.</p></article>
        <article class="card"><span class="card-tag">Sepsis</span><h3 class="card-headline">Breakthrough Sepsis Drug Shows Promise in Phase II</h3><p class="card-body">Australian researchers' treatment showed promising results in <strong>180-patient Phase II trial</strong>, calming dangerous immune reactions.</p></article>
        <article class="card"><span class="card-tag">Cancer Vaccine</span><h3 class="card-headline">Transgene TG4050: Personalized Cancer Vaccine</h3><p class="card-body">Phase I data showing <strong>"striking results"</strong> for individualized cancer vaccine in high-risk head and neck cancer patients.</p></article>
      </div>
    </section>
    <section class="section"><div class="section-header"><h2 class="section-title">What to Watch Tomorrow</h2></div>
      <div class="cards"><article class="card"><p class="card-body"><strong>Retatrutide Phase 3 Completion</strong> — Most powerful weight loss drug approval timeline<br><br><strong>More CRISPR Therapies</strong> — Following Baby KJ's cure, expansion expected<br><br><strong>Oral GLP-1 Approvals</strong> — Orforglipron and competitors seeking FDA nod<br><br><strong>Sepsis Drug Phase III</strong> — Australian breakthrough advancing<br><br><strong>Personalized Cancer Vaccines</strong> — Transgene TG4050 next data readouts</p></article></div>
    </section>
    <section class="section"><div class="bottom-line"><div class="section-header"><h2 class="section-title">Bottom Line</h2></div><p>The GLP-1 revolution is just getting started. Retatrutide's 24% weight loss could reshape the obesity market entirely. The first opioid-free painkiller could help address the addiction crisis. Personalized cancer vaccines and CRISPR cures are moving from theoretical to clinical. India's 98% cost reduction in gene therapy could democratize access globally.</p><p style="margin-top: 1rem; font-weight: 600;">The best healthcare innovations of 2025 will seem quaint by 2030. This is just the beginning.</p></div></section>
  </main>
  <footer class="footer"><p>Health & Wellness Review · Compiled by Sanbot · January 2026</p><p>Updated daily</p></footer>
</body>
</html>
